Skip to main content

Advertisement

SpringerLink
Log in

LUNG CANCER

Dual PD-L1 and CTLA4 inhibition in ES-SCLC

  • In Brief
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • Goldman, J. W. et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30539-8 (2020)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Dual PD-L1 and CTLA4 inhibition in ES-SCLC. Nat Rev Clin Oncol 18, 64 (2021). https://doi.org/10.1038/s41571-020-00466-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-00466-w

  • Springer Nature Limited

Search

Navigation